Business

The global Sickle Cell Anemia Testing and Screening Market is expected to experience significant growth over the next decade as healthcare systems worldwide…

The Clinical, Medical and Regulatory (CMR) department at Novo Nordisk is one of the most diverse and collaborative groups within the organization. From healthcare…

Key PointsAgios stock surged after FDA granted priority review for mitapivat in sickle cell disease.Mitapivat showed mixed Phase 3 results, and competition is…

A new large-scale systematic review and modelling analysis has estimated that more than 8.8 million children and adolescents in sub-Saharan Africa were living with…

The Sickle Cell Anemia Testing and Screening Market offers growth opportunities through expanded newborn testing, molecular diagnostics, and digital workflows.…

Building on its commitment to make insurance more accessible, especially for those affected by chronic or rare diseases, the insurer BNP Paribas Cardif is…

Sickle Cell Disease is included as an EHA 2026 disease-area keyword under non-malignant hematology, with relevant subtypes including Sickle Cell Pain Crises, Vaso-…

Fulcrum Therapeutics said it is discontinuing development of pociredir, its experimental oral treatment for sickle cell disease (SCD), after the U.S. Food and Drug…

Fulcrum Therapeutics has begun a strategic review that may result in it getting sold, a move made after the company’s main medicine hit a possibly insurmountable…

Fulcrum Therapeutics said today it is scrapping its lead pipeline program to develop pociredir as a treatment for sickle cell disease (SCD) and launching a “…